DM199 clinical trials
Also written DM199.
How each study uses DM199 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DM199 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
DiaMedica Therapeutics Inc (7)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test DM199, phase 3 first.
- Dec 2026Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)Phase 2/3 · DiaMedica Therapeutics Inc
Studies
Open first, then newest update. How each study uses DM199 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)RecruitingPhase 2/3DiaMedica Therapeutics IncNCT05065216Written as Recombinant human tissue kallikrein
- Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)CompletedPhase 2DiaMedica Therapeutics IncNCT04123613Written as DM199
- DM199 for Pregnancy ComplicationsWithdrawnNot applicableDiaMedica Therapeutics IncNCT06875141Written as DM199
- Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic StrokeCompletedPhase 2DiaMedica Therapeutics IncNCT03290560Written as Recombinant human tissue kallikrein
- Study to Assess PK, Safety and Tolerability in Patients With DM and CKDCompletedPhase 1DiaMedica Therapeutics IncNCT03795389Written as DM199
- An Open Label, Phase 1b, Ascending Dose Study of DM199CompletedPhase 1DiaMedica Therapeutics IncNCT02868996Written as Recombinant human tissue kallikrein
- A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes PatientsCompletedPhase 1/2DiaMedica Therapeutics IncNCT01845064Written as DM199